Ademuyiwa, Foluso O. http://orcid.org/0000-0002-6766-2258
Chen, Ina
Luo, Jingqin
Rimawi, Mothaffar F.
Hagemann, Ian S.
Fisk, Bryan
Jeffers, Gejae
Skidmore, Zachary L.
Basu, Anamika
Richters, Megan
Ma, Cynthia X.
Weilbaecher, Katherine
Davis, Jennifer
Suresh, Rama
Peterson, Lindsay L.
Bose, Ron
Bagegni, Nusayba
Rigden, Caron E.
Frith, Ashley
Rearden, Timothy P.
Hernandez-Aya, Leonel F.
Roshal, Anna
Clifton, Katherine
Opyrchal, Mateusz
Akintola-Ogunremi, Olaronke
Lee, Byung Ha
Ferrando-Martinez, Sara
Church, Sarah E.
Anurag, Meenakshi
Ellis, Matthew J.
Gao, Feng
Gillanders, William
Griffith, Obi L.
Griffith, Malachi
Funding for this research was provided by:
National Cancer Institute (1K12CA167540, U01 CA214125-03, K22CA188163)
NeoImmnuneTech
Cancer Prevention and Research Institute of Texas (RR140033)
National Institutes of Health (R00HG007940)
Article History
Received: 25 May 2021
Accepted: 18 June 2021
First Online: 26 June 2021
Declarations
:
: FOA reports consulting for Eisai, Immunomedics, AstraZeneca, Athenex, Cardinal Health, Pfizer, AbbVie, Best Doctors, and Advance Medical. FOA reports contracted research for Immunomedics, Pfizer, Seattle Genetics, NeoImmuneTech, RNA Diagnostics, and Astellas. MFR reports consulting for Genentech, MacroGenics, Daiichi, Seattle Genetics, and Novartis. MFR reports contracted research for Pfizer. RB consulting for Genentech. RB reports contracted research for Puma Biotechnology, Inc.
: The protocol and informed consent documents were approved by WUSM and BCM. Upon approval, all participating institutions agreed to follow the Declaration of Helsinki, good clinical practice guidelines, and the applicable parts of the U.S. Code of Federal Regulations.
: Written informed consent was required for enrollment.